Agenus Secures Strategic Finance Deal with Ligand
Company Announcements

Agenus Secures Strategic Finance Deal with Ligand

The latest update is out from Agenus (AGEN).

Agenus Inc. has struck a deal with Ligand Pharmaceuticals, selling a significant portion of its milestone payments and royalties from various licensing agreements, as well as a synthetic royalty on sales of two of its drugs. Ligand will pay Agenus $75 million upfront, with the potential for additional sales reaching up to $200 million, plus an optional $25 million investment. The agreement also includes a warrant for Ligand to purchase Agenus shares, reinforcing the strategic financial move expected to conclude in May 2024.

Find detailed analytics on AGEN stock on TipRanks’ Stock Analysis page.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles